For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230718:nRSR4183Ga&default-theme=true
RNS Number : 4183G e-Therapeutics plc 18 July 2023
e-therapeutics plc
("e-therapeutics" or the "Company")
Result of Annual General Meeting
London, UK, 18 July 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that at its Annual General Meeting
held earlier today, all resolutions, as set out in the Notice of Meeting, were
duly passed.
The votes were as follows:
Resolution Votes For % Votes % Abstentions Resolution Result
Against
Ordinary Resolution 1 370,258,508 100 0 0 0 Passed
Ordinary Resolution 2 370,250,879 99.9 3,463 0.001 4,166 Passed
Ordinary Resolution 3 370,250,879 99.9 3,463 0.001 4,166 Passed
Ordinary Resolution 4 370,255,045 99.9 3,463 0.001 0 Passed
Ordinary Resolution 5 370,196,546 99.9 38,462 0.010 23,500 Passed
Special Resolution 6 370,195,129 99.9 39,879 0.011 23,500 Passed
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551 8888
Timothy Bretherton, Director of Finance and Operations www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)
SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines. The Company's
technology uses computation to capture and model human biology, identify novel
targets, and develop RNAi medicines against those targets that can be rapidly
progressed to the clinic.
ETX's proprietary HepNetTM platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource. The Company generates,
prioritises and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.
GalOmicTM, ETX's proprietary RNAi platform, enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNetTM. The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases. The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmicTM
constructs have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class preclinical RNAi
candidates across several high unmet medical needs in cardiometabolic
indications and targeting promising hepatocyte-expressed targets with effects
in other disease areas. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.
The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGRPMATMTBBBLJ